| Texto completo | |
| Autor(es): Mostrar menos - |
Rodrigues, Maria Gabriela de Almeida
;
Monteiro, Wuelton Marcelo
;
de Melo, Gisely Cardoso
;
Dias, Adila Liliane Barros
;
Sartim, Marco Aurelio
;
Xavier, Mariana Simao
;
Netto, Rebeca Linhares Abreu
;
Almeida, Fernando Fonseca
;
Baia-da-Silva, Djane Clarys
;
Brito-Sousa, Diego
;
de Lacerda, Marcus Vinicius Guimaraes
;
Sampaio, Vanderson de Souza
Número total de Autores: 12
|
| Tipo de documento: | Artigo Científico |
| Fonte: | American Journal of Tropical Medicine and Hygiene; v. 110, n. 6, p. 7-pg., 2024-06-01. |
| Resumo | |
Glucose-6 phosphate dehydrogenase deficiency (G6PDd) was suggested as a risk factor for severe disease in patients with COVID-19. We evaluated clinical outcomes and glucose-6 phosphate dehydrogenase (G6PD) activity during and after illness in patients with COVID-19. This prospective cohort study included adult participants (>= 18 years old) who had clinical and/or radiological COVID-19 findings or positive reverse transcription-polymerase chain reaction results. Epidemiological and clinical data were extracted from electronic medical records. Glucose-6 1 year after discharge. Samples were genotyped for the three most common single nucleotide polymorphisms for G6PDd in the Brazilian Amazon. Seven hundred fifty-three patients were included, of whom 123 (16.3%) were G6PD deficient. There was no difference between groups regarding the risks of hospitalization (P = 0.740) or invasive mechanical ventilation (P = 0.31), but the risk of death was greater in patients with normal G6PD levels (P = 0.022). Only 29 of 116 participants (25%) carried the African G6PDd genotype. Of 30 participants tested as G6PD deficient during disease, only 11 (36.7%) results agreed 1 year after discharge. In conclusion, this study does not demonstrate an association of G6PDd with severity of COVID-19. Limitations of the test for detecting enzyme levels during COVID-19 illness were demonstrated by genotyping and retesting after the disease period. Care must be taken when screening for G6PDd in patients with acute COVID-19. (AU) | |
| Processo FAPESP: | 20/05369-6 - Estratégia acelerada por inteligência artificial para reposicionamento de fármacos contra COVID-19 |
| Beneficiário: | Fabio Trindade Maranhão Costa |
| Modalidade de apoio: | Auxílio à Pesquisa - Regular |